HomeStock ScreenerWockhardtQuarterly Results

Wockhardt Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹164 Cr
QMar 2026
Quarterly Results

In Mar 2026, Wockhardt (WOCKPHARMA) reported revenue ₹1,032 Cr and net profit ₹164 Cr — revenue +36.1% YoY. For annual financials, live price and key ratios, visit WOCKPHARMA stock price BSE.

WOCKPHARMA Quarterly Results — Revenue, Profit & EPS Highlights

Wockhardt latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with WOCKPHARMA fair value to assess whether the stock is under or overvalued.

  • Revenue of ₹1,032 Cr in Mar 2026 (+28.5% vs Sept 2025, +36.1% vs Mar 2025)
  • Net Profit of ₹164 Cr in Mar 2026 (+100.0% vs Sept 2025, +464.4% vs Mar 2025)
  • EBITDA of ₹292 Cr in Mar 2026 (+46.7% vs Sept 2025)
  • Operating Margin of 23.0% in Mar 2026 (+0.0pp vs Sept 2025)
  • Earnings Per Share of ₹10.23 in Mar 2026 (+112.7% vs Sept 2025)

Wockhardt Quarterly Results — Revenue, EBITDA, Net Profit & EPS

WOCKPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 QoQ YoY
Revenue (₹ Cr) 1,032 803 758 758 913 28.5% 36.1%
Net Profit (₹ Cr) 164 82 -45 -108 61 - -
EBITDA (₹ Cr) 292 199 79 -5 192 - -
EPS (₹) 10.23 4.81 -1.57 -5.53 3.61 - -
Operating Margin (%) 23.0% 23.0% 9.0% -3.0% 19.0% - -

WOCKPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results

Wockhardt 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore WOCKPHARMA price trends to track price trends across different timeframes.

Profitability Ratios

Profit Margin 15.9%
EBITDA Margin 28.3%
Operating Margin 23.0%
ROE (Annual) 14.1%

Balance Sheet Highlights

Total Assets ₹8,135 Cr
Total Equity ₹4,657 Cr
Current Assets ₹2,465 Cr
Current Liabilities ₹1,436 Cr

Cash Flow Analysis

Operating Cash Flow ₹-22 Cr
Investing Cash Flow ₹-780 Cr
Financing Cash Flow ₹409 Cr
Net Cash Flow ₹-393 Cr

Current Market Data

Current Price ₹1771.00
Exchange NSE
Last Updated May 27, 2026

WOCKPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Wockhardt latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026
₹442,581.33 Cr 1844.3 15,018 2,710 +1.0% +11.8% 18.0% 163.2
Divis Laboratories
Mar 2026
₹179,363.85 Cr 6797.5 2,986 751 +4.4% +11.8% 25.2% 240.1
Torrent Pharmaceuti…
Mar 2026
₹153,579.77 Cr 4537.8 4,111 364 +27.7% +42.2% 8.9% 394.2
Cipla
Mar 2026
₹114,559.46 Cr 1418.2 6,612 543 -14.3% -4.0% 8.2% 206.4
Dr Reddys Laborator…
Mar 2026
₹110,089.41 Cr 1319.0 7,996 221 -12.5% -11.5% 2.8% 497.7
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores